Phospho-DARPP-32 (Ser97) (D11A5) Rabbit mAb

• 产品编号：CST-3401S      品牌：CST       原厂货号：3401S
• 产品分类：抗体 > 一抗 > 磷酸化抗体
• 应用分类：

描述：

Specificity / Sensitivity

Phospho-DARPP-32 (Ser97) (D11A5) Rabbit mAb detects endogenous levels of DARPP-32 only when phosphorylated at Ser97.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser102 of human DARPP-32 protein (equivalent to Ser97 of mouse DARPP-32 protein).

原厂资料：

Specificity / Sensitivity

Phospho-DARPP-32 (Ser97) (D11A5) Rabbit mAb detects endogenous levels of DARPP-32 only when phosphorylated at Ser97.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser102 of human DARPP-32 protein (equivalent to Ser97 of mouse DARPP-32 protein).

 Background

DARPP-32 (dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000) is a cytosolic protein highly enriched in medium-sized spiny neurons of the neostriatum (1). It is a bifunctional signaling molecule that controls serine/threonine kinase and serine/threonine phosphatase activity (2). Dopamine stimulates phosphorylation of DARPP-32 through D1 receptors and activation of PKA. PKA phosphorylation of DARPP-32 at Thr34 converts it into an inhibitor of protein phosphatase 1 (1). DARPP-32 is converted into an inhibitor of PKA when phosphorylated at Thr75 by cyclin-dependent kinase 5 (CDK5) (2). Mice containing a targeted deletion of the DARPP-32 gene exhibit an altered biochemical, electrophysiological, and behavioral phenotype (3).

Drugs of abuse such as cocaine and food reinforcement learning activate the dopamine D1 receptor-signaling cascade. The downstream effector DARPP-32 is dephosphorylated at Ser97 inhibiting its nuclear export. This enables DARPP-32 to function as an inhibitor of protein phosphatase-1, increasing phosphorylation of histone H3 at Ser10. Knock-in mice bearing a DARPP-32 Ser97 to Ala (S97A) mutation demonstrate changed behavioral effects to drugs of abuse and a decreased motivation for food (4)

1. Nishi, A. et al. (1997) J. Neurosci. 17, 8147-8155.
2. Bibb, J.A. et al. (1999) Nature 402, 669-671.
3. Fienberg, A.A. et al. (1998) Science 281, 838-842.
4. Stipanovich, A. et al. (2008) Nature 453, 879-84.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.